A study of lidocaine jelly for pain relief in women receiving gonadotropin-releasing hormone analog injection during breast cancer treatment

Comparison of pain and anxiety in premenopausal women with hormone receptor-positive breast cancer receiving gonadotropin-releasing hormone analog injection before and after application of topical lidocaine jelly

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN99910605

Enrollment

Registered

2022-12-09

Start date

2019-08-01

Completion date

Unknown

Last updated

2023-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premenopausal women with hormone receptor-positive breast cancer Cancer

Interventions

Questionnaires were used in the evaluation of pain and anxiety experienced during four cycles (1-4th) of GnRHa (goserelin or leuprorelin) injections and recorded as the baseline. Pain and anxiety scor

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Premenopausal women with hormone receptor-positive breast cancer who had undergone breast cancer operations and were indicated for GnRHa injection

Exclusion criteria

Exclusion criteria: 1. Unwilling to receive application of topical lidocaine jelly 2. Refuse questionnaire survey of pain and anxiety score

Design outcomes

Primary

Measure	Time frame
Pain and anxiety measured using a visual analog scale (VAS) at baseline and the 1st to 8th cycles of GnRHa injections	—

Secondary

Measure	Time frame
Levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), and estradiol measured using a blood test before and after the GnRHa injection	—

Countries

Taiwan

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026